By Timothy S. Donahue

Top Takeaways:

• No flavor advantage: FDA scientists found Glas’ flavored pods did not help smokers switch at higher rates than tobacco-flavored pods.
• Authorization still recommended: Regulators concluded age-gating technology sufficiently mitigated youth risk to support authorization.
• Years before approval: Documents show FDA’s OS recommended authorization despite the lack of a demonstrated flavor advantage.

A newly released U.S. Food and Drug Administration scientific review memo shows that agency scientists concluded Glas’ flavored vaping products did not help adult smokers switch from cigarettes at higher rates than tobacco-flavored products, yet the memo still recommended authorization because of the company’s age-verification technology.

The seven-page memorandum, prepared by Dr. Matthew Farrelly, director of the Office of Science at FDA’s Center for Tobacco Products (CTP), offers the clearest explanation to date of why the agency ultimately authorized six products from Glas Inc., including blueberry-, mango-, and menthol-flavored vape pods.

The document is also notable for showing that FDA scientists supported the authorization of the products, offering a glimpse into the agency’s internal scientific review of one of the industry’s most closely watched premarket tobacco product applications (PMTA).

“After scientific evaluation of these applications, FDA found the products to be APPH, subject to specific marketing restrictions and ongoing monitoring requirements,” Farrelly wrote.

At the center of the review was a question that has been debated for years across the nicotine industry: Do flavored vaping products help adult smokers switch away from cigarettes more effectively than tobacco-flavored products? According to the memo, the answer in Glas’ case was no.

The FDA noted that the company submitted a product-specific, randomized, real-world study comparing its blueberry, mango, and menthol products with a tobacco-flavored version of the same device. However, the FDA found that “the data did not demonstrate statistically significant differences in the rates of complete switching among adult smokers or significant cigarette reduction between the flavored new products and tobacco-flavored ENDS.”

The finding is significant because the FDA has historically required flavored vaping products to demonstrate additional public health benefits relative to tobacco-flavored products, given the higher risk of youth appeal associated with flavors.

The memo states that to meet the agency’s “appropriate for the protection of the public health” (APPH) standard, applicants for flavored products must generally either demonstrate an added adult benefit over tobacco flavors or implement sufficiently stringent measures to mitigate youth use.

In Glas’ case, FDA scientists concluded that the company met the second pathway. “CTP concluded that the applicant’s device access restrictions in the device are expected to sufficiently mitigate the risk to youth such that the applications for the four flavored e-liquid products did not need to demonstrate added adult benefit relative to tobacco-flavored ENDS,” the memo states.

The Glas G2 system requires users to download a smartphone application, verify their age and identity with government-issued identification, and periodically revalidate their credentials before the device can be used. The device also automatically locks if it loses connection to the verified smartphone for an extended period.

According to the FDA’s review, studies submitted by the company found that the system was “100% effective” at preventing underage participants in the study from activating the device, while 83% to 96% of adults successfully completed the verification process.

The agency acknowledged limitations in the data, including the relatively small sample of youth participants and uncertainty about real-world performance. Nevertheless, the FDA concluded that the technology was sufficiently robust to alter the public-health analysis typically applied to flavored products.

The memo also found evidence that the products could help adult smokers move away from combustible cigarettes, even if flavored products did not outperform tobacco-flavored products. The FDA cited a three-month randomized study showing complete switching rates of 12% to 18% across all five flavors. The agency noted that published studies have found smoking cessation rates of less than 6% among smokers receiving little or no assistance.

In addition, nearly half of study participants reduced their cigarette consumption by 50% to 99. The review further concluded that the products carried substantially lower estimated lifetime cancer risks than combustible cigarettes. The FDA estimated that the products represented between 1.4% and 10% of the cancer risk associated with conventional cigarettes, although some already-authorized vaping products carry lower estimated risks.

Ultimately, FDA scientists concluded that the benefits outweighed the risks. “The key factors in this decision were: substantial benefit for adult smokers, effective youth protection, lower health risks and appropriate safeguards,” the memo states.

The document concludes with a clear recommendation from the FDA’s scientific review staff. “FDA recommended marketing granted orders” for the rechargeable device, four flavored pod products and one tobacco-flavored pod product.

The document indicates that FDA scientists were willing to recommend authorization for flavored products that failed to demonstrate superior switching benefits compared with tobacco flavor, provided the applicant could sufficiently address concerns about youth access.

That conclusion could have implications far beyond Glas, particularly for manufacturers seeking age-verification technologies and other access-restriction systems for future PMTA submissions.